| Cephalon, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129904 | Liquid Formulations Of Bendamustine - Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described. | 05-24-2012 |
| 20120082726 | SURFACE-TREATED MODAFINIL PARTICLES - The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof. | 04-05-2012 |
| 20120076757 | COMPOSITION FOR TRANSMUCOSAL DELIVERY OF POLYPEPTIDES - The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide. | 03-29-2012 |
| 20120071532 | NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE - Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use. | 03-22-2012 |
| 20120071445 | Combination Therapy for the Treatment of Multiple Myeloma - The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan. | 03-22-2012 |
| 20120041196 | Proteasome Inhibitors and Methods of Using the Same - The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity. | 02-16-2012 |
| 20120035133 | Lyophilization Cakes of Proteasome Inhibitors - Lyophilized cakes of proteasome inhibitors are described, as well as methods for their production and use. | 02-09-2012 |
| 20120028919 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS - The present invention provides a compound of formula I | 02-02-2012 |
| 20120004253 | Novel Fused Pyrrolocarbazoles - The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles. | 01-05-2012 |
| 20120004231 | Substituted Pyridazine Derivatives - The present invention is directed to compounds having histamine H | 01-05-2012 |
| 20110288075 | Pyridazinone Derivatives - The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders. | 11-24-2011 |
| 20110230508 | Novel Forms of a Fused Pyrrolocarbazole Compound - Alternative chemical and/or solid state forms of Compound I, processes to reproducibly make them and methods of treating patients using them. | 09-22-2011 |
| 20110206744 | MODAFINIL FORMULATIONS - The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns. | 08-25-2011 |
| 20110206621 | ORAL TRANSMUCOSAL NICOTINE DOSAGE FORM - The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size. | 08-25-2011 |
| 20110195996 | Transmucosal Treatment Methods in Patients With Mucositis - In accordance with the invention is an fentanyl-containing dosage form designed for transmucosal delivery which includes both an effervescent couple and a pH adjusting substance which can be administered to patients suffering from both pain and mucositis. Also provided is a method of treating pain in a patient having mild oral mucositis by administering a fentanyl-containing dosage form designed for transmucosal delivery. | 08-11-2011 |
| 20110190509 | Processes for the Preparation of Bendamustine - New methods for the preparation of bendamustine, and the pharmaceutical salts thereof, are described. Novel compounds useful for the preparation of bendamustine are also described. | 08-04-2011 |
| 20110190363 | LIQUID FORMULATIONS OF BENDAMUSTINE - Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described. | 08-04-2011 |
| 20110160204 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS - The present invention provides a compound of Formula I | 06-30-2011 |
| 20110144033 | Proteasome Inhibitors and Methods of Using the Same - The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity. | 06-16-2011 |
| 20110124629 | Crystalline Forms of a Pharmaceutical Compound - Described are crystalline forms of the pharmaceutical compound “[9S-(9α,10β,12α)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3 -fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation. | 05-26-2011 |
| 20110098269 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands - The present invention provides compounds according to Formulas I, II, III, IV, V, VI, VII or VIII: | 04-28-2011 |
| 20110071131 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands - The present invention provides compounds of Formula (I): | 03-24-2011 |
| 20110059959 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF - The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer. | 03-10-2011 |
| 20110053920 | SUBSTITUTED BICYCLIC PYRIMIDINES - The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): | 03-03-2011 |
| 20110021583 | ENHANCED TRANSMUCOSAL COMPOSITION AND DOSAGE FORM - The invention provides a transmucosal pharmaceutical composition comprising an active compound, a bile salt and an osmolality adjusting ingredient, wherein the osmolality adjusting ingredient generates a localized hyperosmotic environment and maintains an osmolality level for a period of time sufficient to produce hypertonicity-facilitated transmucosal transport of said active compound across the mucosal tissue. The invention also provides a solid transmucosal dosage form containing the composition, as well as a method of treatment comprising administering the same. In one embodiment, the active compound is a triptan compound, e.g., sumatriptan and zolmitriptan. | 01-27-2011 |
| 20100311752 | Substituted pyridazine derivatives - The present invention is directed to compounds having histamine H | 12-09-2010 |
| 20100298332 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands - The present invention provides compounds of Formula (I): | 11-25-2010 |
| 20100280007 | Pyridazinone Derivatives - The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition. | 11-04-2010 |
| 20100273779 | Pyridazinone Derivatives - The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition. | 10-28-2010 |
| 20100210731 | Modafinil Compositions - Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy. | 08-19-2010 |
| 20100210701 | Novel Forms of Bendamustine Free Base - Novel polymorphic forms of bendamustine free base are described, including amorphous bendamustine free base, six anhydrous crystalline forms, four hydrate forms, and five solvate forms, with methods of their preparation and use also being described. | 08-19-2010 |
| 20100152196 | Novel Fused Pyrrolocarbazoles - The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles. | 06-17-2010 |
| 20100129444 | Novel Pharmaceutical Formulations of Modafinil - The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof. | 05-27-2010 |
| 20100121055 | PROCESSES FOR PREPARING (R)-2-METHYLPYRROLIDINE AND (S)-2-METHYLPYRROLIDINE AND TARTRATE SALTS THEREOF - The present invention provides a short, safe, inexpensive, commercially scalable process for preparing (R)- or (S)-2-methylpyrrolidine from 2-methylpyrroline, which does not require the isolation of synthetic intermediates. | 05-13-2010 |
| 20100112045 | SURFACE-TREATED MODAFINIL PARTICLES - The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof. | 05-06-2010 |
| 20100111902 | COMPOSITION FOR TRANSMUCOSAL DELIVERY OF POLYPEPTIDES - The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide. | 05-06-2010 |
| 20100080829 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to a new lyophilized pharmaceutical composition capable of adhering to oral mucosal tissue for an extended period of time for delivering active pharmaceutical ingredient through the oral mucosal tissue using transmucosal absorption. | 04-01-2010 |
| 20100048576 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS - The present invention provides a compound of Formula I | 02-25-2010 |
| 20090317481 | MODAFINIL FORMULATIONS - The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns. | 12-24-2009 |
| 20090291918 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME - The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity. | 11-26-2009 |
| 20090264488 | NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE - Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use. | 10-22-2009 |
| 20090221555 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS - The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R | 09-03-2009 |
| 20090214442 | Oral Transmucosal Nicotine Dosage Form - Described herein are oral transmucosal solid dosage forms useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the dosage forms transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size. | 08-27-2009 |
| 20090186888 | NOVEL FUSED PYRROLOCARBAZOLES - The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles. | 07-23-2009 |
| 20090155352 | Microemulsion containing indolocarbazole compound and dosage forms containing the same - The invention described herein provides a pharmaceutical composition and oral dosage forms containing the same, having high concentrations of solubilized indolocarbazole compounds as the active ingredient in microemulsion form. The invention also provides a process for increasing the solubilized concentration of indolocarbazole compounds such as lestaurtinib using the addition of water in combination with a hydrophilic component as part of the microemulsion formation process. | 06-18-2009 |
| 20090075936 | Proteasome inhibitors and methods of using the same - The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly or indirectly with proteasome activity. | 03-19-2009 |
| 20090062284 | Thio-Substituted Biarylmethanesulfinyl Derivatives - The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): | 03-05-2009 |
| 20090042907 | Bicyclic aromatic sulfinyl derivatives - The present invention provides compounds of the structure: | 02-12-2009 |
| 20090018202 | Modafinil compositions - Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy. | 01-15-2009 |
| 20090018143 | Thio-substituted arylmethanesulfinyl derivatives - The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): | 01-15-2009 |
| 20080287494 | Transmucosal treatment methods in patients with mucositis - In accordance with the invention is an fentanyl-containing dosage form designed for transmucosal delivery which includes both an effervescent couple and a pH adjusting substance which can be administered to patients suffering from both pain and mucositis. Also provided is a method of treating pain in a patient having mild oral mucositis by administering a fentanyl-containing dosage form designed for transmucosal delivery. | 11-20-2008 |
| 20080207761 | Pharmaceutical formulations of modafinil - Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants. | 08-28-2008 |
